Puma Biotechnology Inc - Common Stock (NQ:PBYI)

10.44 -0.10 (-0.95%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

January 03, 2025

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

December 23, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

November 20, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Where Puma Biotechnology Stands With Analysts ↗

July 26, 2024

Via Benzinga

Puma Biotechnology Reports Third Quarter 2024 Financial Results

November 07, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

October 24, 2024

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 01, 2024

Via Benzinga

Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock ↗

June 04, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

August 06, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Second Quarter Financial Results

August 01, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

July 18, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 07, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

June 03, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

June 02, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Join Russell 3000 Index

May 28, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 23, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗

May 20, 2024

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

Via Benzinga

Topics Intellectual Property

PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 ↗

May 02, 2024

PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Puma Biotechnology Reports First Quarter Financial Results

May 02, 2024

From Puma Biotechnology, Inc.

Via Business Wire

7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗

April 19, 2024

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Via InvestorPlace

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 18, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2024

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

March 20, 2024

From Puma Biotechnology, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 19, 2024

Via Benzinga

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024

From Puma Biotechnology, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.